This page is translated by Google and can contain errors. Go back to English.

Homepage Anticancer Fund

Changemakers on a mission

The Anticancer Fund fills in the blank spaces in cancer research, to deliver more and better treatments.
We offer personalised information about cancer treatments.
Be part of our mission.
Consider your donation not just a contribution, but an investment.
Homepage Anticancer Fund

Our focus

At a glance

29 ongoing clinical trials
1,6 million euros invested in research (in 2023)
1.466 patients supported (last 5 years)
90 scientific publications

Imagine that you are faced with cancer...

A cancer diagnosis turns your world, and that of your loved ones, upside down. Medical terms overwhelms you, and making decisions can be daunting. My Cancer Navigator provides free clear answers and guides you through treatment.
Join the crowdfunding and help us be a compass when cancer makes everything difficult.
Thanks to your support, we can continue to offer and expand My Cancer Navigator, so that we reach more people in need of reliable information about cancer.

Crowdfunding campaign My Cancer Navigator 2024 (2)

Discover our latest news

Pancreatic cancer - joint event Anticancer Fund and Pancreatic Cancer Europe

Pancreatic cancer: joint efforts with Pancreatic Cancer Europe for more therapies

On June 25, 2024, Santiago de Compostela will host a gathering of experts aimed at enhancing treatment options for patients with pancreatic cancer.

Organised by the Anticancer Fund and Pancreatic Cancer Europe, and supported by the European Pancreatic Club, this Multistakeholder Meeting seeks to foster an inclusive dialogue among professionals.

Propranolol in clinical trial angiosarcoma

Exploring beta-blocker propranolol in angiosarcoma treatment

A clinical trial investigated propranolol, commonly used for high blood pressure, as a potential treatment for angiosarcoma, a rare and aggressive cancer. Funded by the Anticancer Fund, the study explored whether propranolol could help control tumour growth before traditional treatments start, aiming to increase the chances of survival.

#iDR24 - An international conference to move drug repurposing forward

The Anticancer Fund champions drug repurposing for cancer at the #iDR24 conference, taking place on March 6 and 7, 2024 in Barcelona. Identifying new uses for existing medicines, represents a significative opportunity for cancer patients.

Childhood solid tumours: first results of paediatric Metro-PD1-study

We present the initial findings of the French-Belgian Metro-PD1 study testing a treatment with nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumours. The study reveals new possible treatment avenues for paediatric solid tumours. The results were published in the European Journal of Cancer.

Dive into our blogs

Food and cancer
Patient question

Can a diet cure your cancer?

Catalysing cancer research: the value of transparent clinical trial data
Science highlights

Catalysing cancer research: the value of transparent clinical trial data

Patient question

The truth about homeopathy and cancer: should you try it?

pioneer trial
Science highlights

Breast cancer research: unlocking novel treatment approaches